Advertisement
Canada markets closed
  • S&P/TSX

    23,956.82
    -77.01 (-0.32%)
     
  • S&P 500

    5,738.17
    -7.20 (-0.13%)
     
  • DOW

    42,313.00
    +137.89 (+0.33%)
     
  • CAD/USD

    0.7400
    -0.0025 (-0.34%)
     
  • CRUDE OIL

    68.57
    +0.90 (+1.33%)
     
  • Bitcoin CAD

    88,844.40
    +1,358.68 (+1.55%)
     
  • XRP CAD

    0.79
    -0.01 (-1.09%)
     
  • GOLD FUTURES

    2,674.00
    -20.90 (-0.78%)
     
  • RUSSELL 2000

    2,224.70
    +14.83 (+0.67%)
     
  • 10-Yr Bond

    3.7490
    -0.0420 (-1.11%)
     
  • NASDAQ

    18,119.59
    -70.70 (-0.39%)
     
  • VOLATILITY

    16.80
    +1.43 (+9.30%)
     
  • FTSE

    8,320.76
    +35.85 (+0.43%)
     
  • NIKKEI 225

    39,829.56
    +903.93 (+2.32%)
     
  • CAD/EUR

    0.6625
    -0.0016 (-0.24%)
     

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Farmer smiles near cannabis crop
Source: Getty Images

Written by Aditya Raghunath at The Motley Fool Canada

Canadian pot stocks such as Aurora Cannabis (TSX:ACB) and Canopy Growth (TSX:WEED) have trailed the broader markets by a wide margin after marijuana was legalized in the country in late 2018. In fact, both marijuana stocks are down 99% below record levels, burning massive investor wealth.

Canadian licensed cannabis producers have wrestled with a slew of industry-wide headwinds that include cannibalization from illegal sales, rising competition, and overvalued acquisitions, all of which resulted in an oversupply of pot products, high inventory levels, and widening losses.

Let’s see if Aurora Cannabis and Canopy Growth can finally stage a turnaround by the end of 2024.

Is Aurora Cannabis a good buy today?

Valued at $424 million by market cap, Aurora Cannabis reported revenue of $83.4 million in the fiscal first quarter (Q1) of 2025 (ended June), an increase of 12% year over year. Aurora Cannabis attributed its top-line growth to plant propagation revenue, which rose 16% to $23.1 million. While medical marijuana sales were up 13%, its retail cannabis declined by 10%.

In the last two years, Aurora Cannabis has moved away from the retail cannabis market and focused on the higher-margin medical marijuana segment. It also acquired a controlling interest in Bevo, a plant propagation business. Bevo is among the largest suppliers of vegetable plants in North America and provides Aurora Cannabis with an opportunity to diversify its revenue and lower its reliance on the competitive retail cannabis business.

In the last 12 months, Aurora Cannabis has reported revenue of $279 million, an increase of 12.3% year over year. Moreover, it ended the June quarter with a gross margin of more than 53%, compared to just 6.6% in fiscal 2023.

Its improving profitability allowed Aurora Cannabis to report a free cash flow for the first time in fiscal Q1. However, investors should note that the free cash flow could fluctuate depending on the timing of receivables collected and the payment of liabilities.

Aurora Cannabis is focused on expanding into other international markets and growing operations, which should improve revenue and earnings growth in the near term. Analysts tracking ACB stock expect it to gain 22% in the next 12 months.

Is Canopy Growth stock undervalued?

Valued at $678 million by market cap, Canopy Growth closed its retail operations in Canada in early 2023, offloading 28 company-owned stores under brands such as Tokyo Smoke and Tweed. While the retail cannabis segment initially looked promising, the rise in competition has led to lower product prices and massive losses for Canopy Growth and its peers.

In fiscal Q1 of 2025 (ended in June), Canopy Growth reported sales of $66.2 million, down 13% year over year. However, its gross profit rose by 67% to $23 million due to its cost-savings program, lower inventory write-downs and a transition towards higher-margin medical marijuana products.

Despite increasing its gross margins by 1700 basis points, Canopy Growth remains unprofitable and reported an operating loss of $21.3 million. Additionally, its free cash outflow stood at $55.7 million, compared to an outflow of $150.6 million in the year-ago period.

The Foolish takeaway

While Aurora Cannabis and Canopy Growth are improving their profit margins, both companies remain high-risk investments at current multiples. The pot stocks should showcase an ability to consistently deliver organic growth, service debt payments, and generate enough cash flow to fuel their expansion plans and gain investor confidence.

The post Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4? appeared first on The Motley Fool Canada.

Should you invest $1,000 in Aurora Cannabis right now?

Before you buy stock in Aurora Cannabis, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Aurora Cannabis wasn’t one of them. The 10 stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $21,758.28!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 31 percentage points since 2013*.

See the 10 stocks * Returns as of 9/16/24

More reading

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

2024